Characterization of the interaction between von Willebrand factor and osteoprotegerin

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 9, 2007, Pages 1956-1962

  Shahbazi, S ^a,b   Lenting, P J ^c   Fribourg, C ^a,b   Terraube, V ^a,b   Denis, C V ^a,b   Christophe, Oliver D ^a,b,d  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Endothelial cells; Factor; Osteoprotegerin; Von Willebrand; Weibel Palade bodies

Indexed keywords

BIOCHEMICAL MARKER; OSTEOPROTEGERIN; VON WILLEBRAND FACTOR;

ARTERY CALCIFICATION; ARTICLE; BINDING AFFINITY; BLOOD VESSEL INJURY; COMPLEX FORMATION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INFLAMMATION; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TRANS GOLGI NETWORK;

AMINO ACID SEQUENCE; CELLS, CULTURED; HUMANS; OSTEOPROTEGERIN; PROTEIN BINDING; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; VON WILLEBRAND FACTOR;

EID: 34548093193     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02681.x     Document Type: Article

References (24)

1. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 257-79.
2. Denis CV. Molecular and cellular biology of von Willebrand factor. Int J Hematol 2002; 75: 3-8.
3. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714-23.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89: 309-19.
5. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-57.
6. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323-31.
7. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991; 196: 369-75.
8. Lankhof H, van Hoeij M, Schiphorst ME, Bracke M, Wu YP, Ijsseldijk MJ, Vink T, de Groot PG, Sixma JJ. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996; 75: 950-8.
9. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, Tsai HM, de Groot PG, Sixma JJ, Vink T. von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost 1997; 77: 1008-13.
10. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-9.
11. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005; 106: 3035-42.
12. Girma JP, Chopek MW, Titani K, Davie EW. Limited proteolysis of human von Willebrand factor by Staphylococcus aureus V-8 protease: Isolation and partial characterization of a platelet-binding domain. Biochemistry 1986; 25: 3156-63.
13. Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem 1974; 22: 1084-91.
14. Pietu G, Ribba AS, Cherel G, Siguret V, Obert B, Rouault C, Ginsburg D, Meyer D. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb Haemost 1994; 71: 788-92.
15. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994; 83: 3536-44.
16. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): Energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006; 281: 30400-11.
17. Kim JH, Johannes L, Goud B, Antony C, Lingwood CA, Daneman R, Grinstein S. Noninvasive measurement of the pH of the endoplasmic reticulum at rest and during calcium release. Proc Natl Acad Sci USA 1998; 95: 2997-3002.
18. Anderson RG, Orci L. A view of acidic intracellular compartments. J Cell Biol 1988; 106: 539-43.
19. Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991; 115: 1505-19.
20. Sengel A, Stoebner P. Golgi origin of tubular inclusions in endothelial cells. J Cell Biol 1970; 44: 223-6.
21. Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE, Cutler DF. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006; 10: 223-32.
22. Hannah MJ, Williams R, Kaur J, Hewlett LJ, Cutler DF. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol 2002; 13: 313-24.
23. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood 2006; 107: 3922-4.
24. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 4072-7.